NCT07091487 (D-HOMES R01) is a NA clinical trial of Diabetes Homeless Medication Support in Type 2 Diabetes, sponsored by Katherine Vickery.

Who is sponsoring NCT07091487?

NCT07091487 is sponsored by Katherine Vickery.

What drugs are being tested in NCT07091487?

Interventions in NCT07091487: Diabetes Homeless Medication Support, Enhanced Usual Care/ Education.

What condition does NCT07091487 study?

NCT07091487 studies Type 2 Diabetes.

Is NCT07091487 still recruiting?

NCT07091487 is currently recruiting now. Last updated 29 July 2025.

Last reviewed 2025-07-29 · How we verify

NCT07091487: D-HOMES R01

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effectiveness of the Diabetes Homeless Medication Support (D-HOMES) Program on Diabetes Management

Recruiting now NA Last updated 29 July 2025

What this trial tests

NA trial testing Diabetes Homeless Medication Support in Type 2 Diabetes in 256 participants. Currently enrolling.

Timeline

25 June 2025

Primary endpoint
30 December 2028

30 September 2029

Quick facts

Lead sponsor	Katherine Vickery
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	256
Start date	25 June 2025
Primary completion	30 December 2028
Estimated completion	30 September 2029
Sites	1 location across United States

Drugs / interventions tested

Diabetes Homeless Medication Support
Enhanced Usual Care/ Education

Conditions studied

Type 2 Diabetes — all drugs for Type 2 Diabetes →

Sponsor

Katherine Vickery

Who can join

18 and older, any sex, with Type 2 Diabetes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trial is to learn if the Diabetes Homelessness Medication Support (D-HOMES) wellness coaching model is effective for adults who speak English or Spanish, have Type 2 diabetes with an HbA1c at or above 7.5, and have recently experienced homelessness. Researchers will compare a one-time education session about diabetes to 10 wellness coaching sessions to see if there are differences between the groups' health outcomes. The main questions it aims to answer are: * Do D-HOMES participants have greater reductions in HbA1c at 3 months than participants who received education? * Do D-HOMES participants have greater reductions in HbA1c at 6 and 12 months compared to those who received education? * Do D-HOMES participants have improvements in blood pressure control, quality of life, self-reported psychological wellness, diabetes distress, and diabetes medication adherence and self-management at 3, 6, and 12 months? * What factors must be considered to make D-HOMES scalable? Participants will: * complete 5 assessments including two baseline assessments and follow-ups at months 3,6, and 12 * participate in a one-time education session or 10 weeks of wellness coaching.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Type 2 Diabetes

Currently open trials in the same condition.

NCT07053319 — SGLT2i, Pioglitazone, and Ketone Production in T2D · Phase 1 · recruiting
NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07463859 — Effects of Periodontal Treatment Associated With Antimicrobial Photodynamic Therapy on Halitosis in Patients With Diabet · NA · recruiting
NCT07254689 — The Food for Health Study · NA · recruiting
NCT07558863 — Effect of GLP-1RA on Cardiac Autonomic Neuropathy in Type 2 Diabetes · Phase 4 · recruiting

Other Katherine Vickery trials

Trials by the same sponsor.

NCT06025721 — Behavior Change Intervention for Cardiovascular Risk Reduction Among People Experiencing Homelessness · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07091487 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Katherine Vickery
Last refreshed: 29 July 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07091487.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing